{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:05:08Z","timestamp":1772442308327,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.mayocp.2025.12.003","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:27:14Z","timestamp":1772440034000},"page":"453-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Management of Systemic Cancer Therapies for Solid Organ and Hematologic Malignant Neoplasms: Recommendations From the Emory University Systemic Therapies Perioperative Management Group"],"prefix":"10.1016","volume":"101","author":[{"given":"Jonathan M.","family":"Morris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaybrielle R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalise E.","family":"Labatut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-7066","authenticated-orcid":false,"given":"Danielle E.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shervin V.","family":"Oskouei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Culley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocp.2025.12.003_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.mayocp.2025.12.003_bib2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djad020","article-title":"Changes in survival in de novo metastatic cancer in an era of new medicines","volume":"115","author":"Luyendijk","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.mayocp.2025.12.003_bib3","series-title":"Elimination Half-life of Drugs","author":"Hallare","year":"2025"},{"issue":"2","key":"10.1016\/j.mayocp.2025.12.003_bib4","first-page":"S1","article-title":"Clinical consensus statement development manual","volume":"153","author":"Rosenfeld","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"10.1016\/j.mayocp.2025.12.003_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.mayocp.2025.12.003_bib6","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2025.12.003_bib7","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.mayocp.2025.12.003_bib8","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.mayocp.2025.12.003_bib9","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials","volume":"3","author":"Long","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10336","key":"10.1016\/j.mayocp.2025.12.003_bib10","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.mayocp.2025.12.003_bib11","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2025.12.003_bib12","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.mayocp.2025.12.003_bib13","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2025.12.003_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2025.12.003_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11912-022-01202-6","article-title":"Cancer immunotherapies: what the perioperative physician needs to know","volume":"24","author":"Ackerman","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"17","key":"10.1016\/j.mayocp.2025.12.003_bib16","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.mayocp.2025.12.003_bib17","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2014.55.6993","article-title":"Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor\u2013positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group","volume":"32","author":"Tevaarwerk","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2025.12.003_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijsu.2012.05.001","article-title":"Stopping tamoxifen peri-operatively for VTE risk reduction: a proposed management algorithm","volume":"10","author":"Hussain","year":"2012","journal-title":"Int J Surg"},{"issue":"10","key":"10.1016\/j.mayocp.2025.12.003_bib19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2025.12.003_bib20","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cancers13051103","article-title":"Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease","volume":"13","author":"von Hundelshausen","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.mayocp.2025.12.003_bib21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2025.12.003_bib22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625166329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625166329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:27:28Z","timestamp":1772440048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619625166329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0025619625166329"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.12.003","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Management of Systemic Cancer Therapies for Solid Organ and Hematologic Malignant Neoplasms: Recommendations From the Emory University Systemic Therapies Perioperative Management Group","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}